Ms LINDA SMIBERT
Kowa Company, Ltd is a privately-held Japanese corporation headquartered in Nagoya. Since its establishment as a textile wholesaler in 1894, Kowa has grown into a multinational company with 48 affiliates around the world and has built a strong position in developing, manufacturing, marketing and trading products within a variety of businesses. Kowa started its pharmaceutical business in 1947, and has since built a strong presence in the Japanese prescription and OTC drug markets and it is growing rapidly overseas.
Areas of Interest
• Cardiovascular
• Metabolic Syndromes
• Pain Management
• Auto-inflammatory
• Gastroenterological
Partnership Structures
• Co-development
• Co-commercialization
• Licensing
• Across all stages of development & commercialization
KOWA PHARMA
Sr.Director,Operations & Business Development
Ralph Solarski
Kimberly-Clark has developed an innovative transdermal drug delivery technology for Biologics. The Biologic Transdermal System is designed to deliver large molecular weight biologics (demonstrated up to 150,000 Daltons) without a pump or other secondary device. Kimberly-Clark has a rich heritage of providing innovative, high quality products for both consumer and B2B markets, including its $1.5 billion healthcare division that manufactures and markets a broad range of medical devices and medical supplies.
Kimberly-Clark
Director, Business Development & StrategyMr Bryan Stuart
Civitas is a privately-held pharmaceutical company focused on developing a robust pipeline of inhaled therapeutics with the clinically proven ARCUS(TM) dry powder platform. The company’s lead program for Parkinson’s disease, CVT-301, is intended to treat intermittent and debilitating motor fluctuations resulting from an inadequate response to patients’ standard oral medications. CVT-301 is currently enrolling a Phase 2 dose ranging study following the completion of a successful Phase 1 study which established clinical pharmacokinetic proof-of-concept at end of 2011. The product portfolio includes additional programs in respiratory disease, CNS disorders and infectious disease.
Civitas Therapeutics
Chief Business OfficerMr Thadd Vargas
Depomed, Inc. (Nasdaq: DEPO) is a US based specialty pharmaceutical company with a focus in pain, CNS, and Women's Health. The company has advanced three products to market and has developed a pipeline with late-stage product opportunities intended to address common medical conditions affecting large patient populations
Depomed is currently seeking US co-promotion, and Global license partners for it's marketed product Gralise (once-daily gabapentin for Post Herpetic Neuralgia), and Serada a non-hormonal treatment for Vasomotor Symptoms (menopausal hot flashes) which is currently under in registration.
Depomed
SVP Business Development
Dr Gonul Velicelebi
CalciMedica is a clinical stage biotechnology company dedicated to the discovery and development of oral drugs to treat inflammatory and autoimmune diseases and organ transplant rejection. CalciMedica’s compounds are selective and potent inhibitors of the calcium release-activated calcium (CRAC) channels. The CRAC channel activates a signaling pathway that is essential for the adaptive immune response in T cells. The therapeutic value of inhibiting this pathway has been established by calcineurin inhibitors, a class of immunosuppressants that work downstream from the CRAC channel. Furthermore, the CRAC channel has been validated as a drug target in humans through the identification of a loss-of-function mutation. CalciMedica has discovered several potent and selective CRAC channel inhibitors (CCIs) that show anti-inflammatory activity in animal models. CalciMedica is developing its first clinical compound, CM2489, for the treatment of moderate-to-severe plaque psoriasis. CalciMedica recently completed a multiple-dose Phase 1 study with CM2489 in psoriasis patients and shown it to be safe, well-tolerated, and well-behaved with evidence of clinical improvement. CM2489 is the first CRAC channel inhibitor, or CCI, to be tested in humans. CalciMedica's pipeline of structurally diverse, potent and selective CRAC channel inhibitors has the potential to become a therapeutic platform, targeting multiple autoimmune indications.
